Hypertension is the key modifiable risk factor for stroke [17], systemic RAS blockade, with ACE inhibitors (ACEi) or Ang II type 1 receptor (AT1R) antagonists (angiotensin receptor blockers; ARBs), is a common therapy for treating hypertension [18] and with efficient BP control the risk of stroke is reduced [19,20]. This evidence concerns the gene ACE and Hypertension.